Business
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
SANTA CLARA, Calif., March 11, 2026--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States.
About this update from Agilent Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":404,"url":"https://media.zenfs.com/en/business-wire.com/c2604dc1691b9bcd09b2d61707d5a1fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YworKG4vz4g1lftMXCyL8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c2604dc1691b9bcd09b2d61707d5a1fb","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TYDzwphto0_D3ISNhafNtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD04MDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c2604dc1691b9bcd09b2d61707d5a1fb","width":1000,"height":404}},"lazy":false},{"type":"text","content":"SANTA CLARA, Calif., March 11, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States.","length":314,"tagName":"p"},{"type":"text","content":"Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions.","length":208,"tagName":"p"},{"type":"text","content":"Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides customers streamlined access to end-to-end development and manufacturing services through a single partner — from discovery and process development through clinical- and commercial-scale manufacturing.","length":424,"tagName":"p"},{"type":"text","content":""The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership in this space," said Agilent President and CEO, Padraig McDonnell. "For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life-changing therapies to patients."","length":444,"tagName":"p"},{"type":"text","content":"Simon May, p...